We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Eli Lilly Disputes New York Times Report

Law360 (December 18, 2006, 12:00 AM EST) -- Eli Lilly & Co. downplayed the risks of its schizophrenia and bipolar disorder drug Zyprexa while also encouraging doctors to prescribe the drug for patients that had neither condition, according to company marketing documents.

A lawyer for patients gave the documents to the New York Times. The newspaper said that Lilly executives kept important information from doctors about Zyprexa’s ties to obesity and its tendency to raise blood sugar, both of which cause diabetes.

The Times said that Lilly’s published data has shown that 30% of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.